The leukapheresis market was sized at USD 71.4 million in 2022, which will power at a rate of 8.4% in the years to come, to touch USD 136.3 million by 2030.
 |
| To learn more about this report: https://bit.ly/3FDIFaP |
The market is bifurcated into devices and disposables, depending on product, of which disposables held the dominating share in 2022, a situation that will likely remain unchanged.
The growing requirement for leukapheresis disposables because of the increasing leukemia occurrence is the key driver for the industry growth. Furthermore, the correct use of a number of disposables has the advantage of lowering the danger of infections throughout blood transfusions.
Research application had the larger revenue share, about 80%, in 2022, and it will maintain its dominance in the years to come. This is generally as a result of the rising use of leukapheresis products for the creation of cell-based immunotherapies, increasing requirement for leukopaks in scientific research, and mounting acceptance of leukapheresis-derived primary cells in pharma R&D.
North America leukapheresis market had the largest share, of about 50%, in 2022, and it will grow at a healthy rate, according to P&S Intelligence. This will be as a result of the considerable R&D activities in the pharma and biotech sectors.
Moreover, the industry is developing because of the government programs for supporting healthy lifestyles and raise consciousness and the tech improvements in hematology.
Furthermore, the development in the cancer hospitals network and blood donation and processing centers contributes to the industrial growth.
It is because of the increasing number of initiatives of the government for raising cancer awareness, the demand for leukapheresis will increase considerably in the years to come.
